19.56
+1.38(+7.59%)
Currency In USD
| Previous Close | 18.18 |
| Open | 18.55 |
| Day High | 19.91 |
| Day Low | 18.13 |
| 52-Week High | 22.3 |
| 52-Week Low | 2.76 |
| Volume | 5.42M |
| Average Volume | 2.36M |
| Market Cap | 2.04B |
| PE | -9.1 |
| EPS | -2.15 |
| Moving Average 50 Days | 8.63 |
| Moving Average 200 Days | 5.49 |
| Change | 1.38 |
If you invested $1000 in Alumis Inc. Common Stock (ALMS) since IPO date, it would be worth $1,470.68 as of January 10, 2026 at a share price of $19.56. Whereas If you bought $1000 worth of Alumis Inc. Common Stock (ALMS) shares 1 year ago, it would be worth $1,470.68 as of January 10, 2026 at a share price of $19.56.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
11 hours ago
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the clos
Alumis Announces Pricing of Upsized Public Offering of Common Stock
GlobeNewswire Inc.
Jan 08, 2026 3:52 AM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pric
Alumis Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
Jan 06, 2026 9:12 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced its plan